Trk Receptor
Tropomyosin related kinase receptor
Trk receptors are a family of three receptor tyrosine kinases (TrkA, TrkB, and TrkC), each of which can be activated by one or more of four neurotrophins-nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), and neurotrophins 3 and 4 (NT3 and NT4).
TrkA, TrkB, and TrkC are transmembrane proteins that comprise the TRK receptor family. These receptor tyrosine kinases are expressed in human neuronal tissue, and play an essential role in both the physiology of development and function of the nervous system through activation by neurotrophins (NTs). The latter are specific ligands known as NGF for TrkA, BDGF, and NT-4/5 for TrkB and NT3 for TrkC, respectively.
The binding of the ligand to the receptor triggers the oligomerisation of the receptors and phosphorylation of specific tyrosine residues in the intracytoplasmic kinase domain. This event results into the activation of signal transduction pathways leading to proliferation, differentiation and survival in normal and neoplastic neuronal cells.
Trk Receptor Isoform Specific Products
All Product Categories
-
Trk Receptor Inhibitors
(147)
View all products
-
Trk Receptor Agonists
(13)
View all products
-
Trk Receptor Antagonists
(4)
View all products
-
Trk Receptor Activators
(24)
View all products
-
Trk Receptor Modulators
(4)
View all products
-
Trk Receptor Degraders
(5)
View all products
-
Trk Receptor Controls
(4)
View all products
-
Trk Receptor Ligands
(2)
View all products
-
Trk Receptor Related Products (219)
Related Products (219)
-
Antibodies (9)
-
Trk Receptor Isoform Comparison
-
TRK-IN-31
0 ImagesCat. No.: HY-174330TRK-IN-31 is an orally active TRK inhibitor with an IC50 of 1.8 nM. TRK-IN-31 has superior antiproliferative activity in the Ba/F3-MPRIP-TRKAG667C cells, and potently inhibits TRK kinase activity with high selectivity. TRK-IN-31 significantly inhibits tumor growth in Ba/F3-MPRIP-TRKAG667C subcutaneous tumor mice model.
-
TRK-IN-15
0 ImagesCat. No.: HY-146521CAS No.: 1365213-20-2TRK-IN-15 is a potent inhibitor of TRK. Protein kinases play a critical role in the control of cell growth and differentiation and are responsible for the control of a wide variety of cellular signal transduction processes. TRK-IN-15 has the potential for the research of TRK-related diseases (extracted from patent WO2012034091A1, compound X-55).
-
TRK-IN-32
0 ImagesCat. No.: HY-175302CAS No.: 3044124-79-7TRK-IN-32 is a potent TRK inhibitor. TRK-IN-32 potently inhibits TRKWT, TRKG595R and TRKG667C with IC50 values of 0.08 nM, 2.14 nM and 0.68 nM, respectively. TRK-IN-32 also demonstrates antiproliferative activity against a panel of Ba/F3 cell lines transformed with wild type, xDFG, solvent-front as well as gatekeeper mutant TRK fusion proteins. TRK-IN-32 induces apoptosis of Ba/F3-TRKAWT and Ba/F3-TRKAG667C cells.TRK-IN-32 can be used for the study of various cancers (such as thyroid cancer, secretory breast carcinoma).
-
PTX-BD10-2
0 ImagesCat. No.: HY-148750CAS No.: 1627834-10-9Synonyms: BD10-2PTX-BD10-2 (BD10-2) is an orally active TrkB/C modulator. PTX-BD10-2 ameliorates BFCN degeneration. PTX-BD10-2 restores cholinergic neurite integrity, alleviates cholinergic neurite atrophy. PTX-BD10-2 can be used in the research of Alzheimer's disease.
-
Levomilnacipran-d5 hydrochloride
0 ImagesCat. No.: HY-B0168BSSynonyms: (1S,2R)-Milnacipran-d5 hydrochloride; F-2695-d5 hydrochlorideLevomilnacipran-d5 ((1S,2R)-Milnacipran-d5) hydrochloride is deuterium labeled Levomilnacipran hydrochloride (HY-B0168B). Levomilnacipran ((1S,2R)-Milnacipran) hydrochloride is the enantiomer of Milnacipran (HY-B0168) and a strong substrate of P-gp that can cross the blood-brain barrier. Levomilnacipran hydrochloride is a serotonin and norepinephrine reuptake inhibitor, with IC50 values of 10.5 nM and 19.0 nM, and Ki values of 92.2 nM and 1.2 nM for human norepinephrine transporter (NET) and serotonin transporter (SERT), respectively. Levomilnacipran hydrochloride has antidepressant and anxiolytic activities. Levomilnacipran hydrochloride can be used for the research of depression.
-
Phenylmethyl 6-O-α-L-arabinofuranosyl-β-D-glucopyranoside
0 ImagesCat. No.: HY-N15532CAS No.: 88510-11-6Phenylmethyl 6-O-α-L-arabinofuranosyl-β-D-glucopyranoside (Compound 12) is a nerve growth factor (NGF) secretion promoter, which is found in plants of the genus Piper. Phenylmethyl 6-O-α-L-arabinofuranosyl-β-D-glucopyranoside is promising for research of neurodegenerative diseases (such as Parkinson's disease and Alzheimer's disease) and diabetic polyneuropathy.
-
TRKB(NTRK2) Recombinant Human Active Protein Kinase
0 ImagesCat. No.: HY-E70870TRKB(NTRK2) is a member of tyrosine kinase gene family. TRKB is the primary receptor for brain-derived nerve growth factor (BDNF) and neurotrophin 4/5 (NT4/5). TRKB(NTRK2) Recombinant Human Active Protein Kinase is a recombinant TRKB(NTRK2) protein that can be used to study TRKB(NTRK2)-related functions.
-
Trk-IN-20
0 ImagesCat. No.: HY-150561CAS No.: 2460924-63-2Trk-IN-20 is a kind of 3-vinylindazole derivatives. Trk-IN-20 suppresses Trk kinases functions by phosphorylation inhibition of TrkA/B/C with IC50 values of 1.6 nM, 2.9 nM and 2.0 nM, respectively.
-
TRK-IN-23
0 ImagesCat. No.: HY-149965CAS No.: 2924344-29-4
-
TRK-IN-16
0 ImagesCat. No.: HY-146522CAS No.: 1365212-81-2TRK-IN-16 is a potent inhibitor of TRK. Protein kinases play a critical role in the control of cell growth and differentiation and are responsible for the control of a wide variety of cellular signal transduction processes. TRK-IN-16 has the potential for the research of TRK-related diseases (extracted from patent WO2012034091A1, compound X-21).
-
TRK-IN-26
0 ImagesCat. No.: HY-160166CAS No.: 2412309-52-3
-
GR2-128
0 ImagesCat. No.: HY-184396GR2-128 is a dual inhibitor targeting MLK3 and NAMPT with IC50 values of 84 nM and 14 nM, respectively. GR2-128 inhibits downstream JNK/c‑Jun signaling and reduces NAD+ levels. GR2-128 exhibits antiproliferative and pro-apoptotic activities in triple-negative breast cancer cells without significant toxicity to normal cells. GR2-128 suppresses tumor growth, reduces macrophage and neutrophil infiltration, and increases tumor T-cell markers in a syngeneic mouse model, and can be used for triple-negative breast cancer research.
-
ZW-18-116
0 ImagesCat. No.: HY-180550ZW-18-116 (compound 9) is a dual-target PROTAC degrader for the oncoproteins TRKA and RET. ZW-18-116 induces the degradation of oncoproteins TRKA and RET by recruiting the CRBN E3 ligase. ZW-18-116 exhibits potent anti-proliferative activity in various cancer cell lines harboring RET or TRKA fusions. ZW-18-116 can be used for RET or TRKA-derived cancer research, such as thyroid, lung, and colon cancers.
-
RET/TRKA-IN-1
0 ImagesCat. No.: HY-161775CAS No.: 3048634-52-9
-
(3S,4R)-PF-6683324
0 ImagesCat. No.: HY-112436ACAS No.: 1799789-00-6
-
TIY-7
0 ImagesCat. No.: HY-146755CAS No.: 2846435-83-2TIY-7 is a selective and orally active tropomyosin receptor kinase (TRK) inhibitor. TIY-7 shows enzyme inhibitory activity with IC50s of 2.9, 1.1, 0.7, 0.8, 0.8, 0.2 nM for TRKA, TRKAG595R, TRKAG667C, TRKAF589L, TRKCG623R, TRKCG696A, respectively. TIY-7 shows anti-tumor potency in mouse xenograft model.
-
TRK-IN-14
0 ImagesCat. No.: HY-146519CAS No.: 1365212-84-5TRK-IN-14 is a potent inhibitor of TRK. Protein kinases play a critical role in the control of cell growth and differentiation and are responsible for the control of a wide variety of cellular signal transduction processes. TRK-IN-14 has the potential for the research of TRK-related diseases (extracted from patent WO2012034091A1, compound X-47).
-
IGF-1R modulator 1
0 ImagesCat. No.: HY-402309CAS No.: 2375424-89-6IGF-1R modulator 1 (Example 5) is an IGF-1R modulator, with EC50s of 0.29 μM (FGFR1), 0.25 μM (IGF1R), 0.34 μM (TrkA), 0.39 μM (TrkB). IGF-1R modulator 1 can be used for research of diseases characterised by impaired signalling of neurotrophins and/or other trophic factors, such as Alzheimer's disease.
